Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib—A cost-effectiveness analysis

PLoS ONE ◽

10.1371/journal.pone.0207132 ◽

2018 ◽

Vol 13 (11) ◽

pp. e0207132 ◽

Author(s):

Amir Shlomai ◽

Moshe Leshno ◽

Daniel A. Goldstein

Keyword(s):

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis

Download Full-text

P-2 First-line atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma: A cost-effectiveness analysis

Annals of Oncology ◽

10.1016/j.annonc.2021.05.057 ◽

2021 ◽

Vol 32 ◽

pp. S97

Author(s):

S. Chan ◽

C. Chiang ◽

S. Lee ◽

H. Choi

Keyword(s):

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis

Download Full-text

Atezolizumab and bevacizumab combination compared with sorafenib as the first‐line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost‐effectiveness analysis in China and the United states

Liver International ◽

10.1111/liv.14795 ◽

2021 ◽

Vol 41 (5) ◽

pp. 1097-1104

Author(s):

Feng Wen ◽

Hanrui Zheng ◽

Pengfei Zhang ◽

Weiting Liao ◽

Kexun Zhou ◽

...

Keyword(s):

United States ◽

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Systemic Treatment ◽

The United States ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Unresectable Hepatocellular Carcinoma

Download Full-text

Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis

Value in Health ◽

10.1016/j.jval.2016.09.2397 ◽

2017 ◽

Vol 20 (3) ◽

pp. 336-344 ◽

Author(s):

Carla Rognoni ◽

Oriana Ciani ◽

Silvia Sommariva ◽

Rosanna Tarricone

Keyword(s):

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Real World Data ◽

Transarterial Radioembolization ◽

Effectiveness Analysis

Download Full-text

Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan

Journal of Gastroenterology ◽

10.1007/s00535-019-01554-0 ◽

2019 ◽

Vol 54 (6) ◽

pp. 558-570 ◽

Author(s):

Masahiro Kobayashi ◽

Masatoshi Kudo ◽

Namiki Izumi ◽

Shuichi Kaneko ◽

Mie Azuma ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Unresectable Hepatocellular Carcinoma

Download Full-text

PIH31 COST-EFFECTIVENESS ANALYSIS OF REGORAFENIB AS A SECOND-LINE THERAPY IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA IN CHINA

Value in Health ◽

10.1016/j.jval.2019.04.831 ◽

2019 ◽

Vol 22 ◽

pp. S187-S188

Author(s):

D. Xiao ◽

S. Zhu ◽

W. Sun ◽

J. Xuan

Keyword(s):

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Second Line ◽

Second Line Therapy ◽

Effectiveness Analysis ◽

Download Full-text

Cost-Effectiveness Analysis of Stereotactic Ablative Body Radiation Therapy Compared With Surgery and Radiofrequency Ablation in Two Patient Cohorts: Metastatic Liver Cancer and Hepatocellular Carcinoma

Clinical Oncology ◽

10.1016/j.clon.2020.08.010 ◽

2020 ◽

Author(s):

H. Jin ◽

A. Chalkidou ◽

M. Hawkins ◽

J. Summers ◽

S. Eddy ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Radiation Therapy ◽

Cost Effectiveness ◽

Radiofrequency Ablation ◽

Liver Cancer ◽

Cost Effectiveness Analysis ◽

Metastatic Liver Cancer ◽

Effectiveness Analysis ◽

Metastatic Liver

Download Full-text

Cost–effectiveness analysis of treatments involving radioembolization in intermediate-stage hepatocellular carcinoma

Journal of Comparative Effectiveness Research ◽

10.2217/cer-2017-0050 ◽

2018 ◽

Vol 7 (3) ◽

pp. 209-221 ◽

Author(s):

Carla Rognoni ◽

Oriana Ciani ◽

Silvia Sommariva ◽

Rosanna Tarricone

Keyword(s):

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Intermediate Stage ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis

Download Full-text

Early detection and curative treatment of hepatocellular carcinoma: A cost-effectiveness analysis in France and in the United States

10.1002/hep.28961 ◽

2017 ◽

Vol 65 (4) ◽

pp. 1237-1248 ◽

Author(s):

Benjamin Cadier ◽

Julie Bulsei ◽

Pierre Nahon ◽

Olivier Seror ◽

Alexis Laurent ◽

...

Keyword(s):

United States ◽

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Early Detection ◽

The United States ◽

Cost Effectiveness Analysis ◽

Curative Treatment ◽

Effectiveness Analysis

Download Full-text

Oxaliplatin plus fluorouracil/leucovorin or sorafneib as first-line treatments for advanced hepatocellular carcinoma: a cost-effectiveness analysis.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.e18270 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. e18270-e18270

Author(s):

Pengfei Zhang ◽

Feng Wen ◽

Qiu Li

Keyword(s):

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Advanced Hepatocellular Carcinoma ◽

Effectiveness Analysis

Download Full-text

1328: Cost-Effectiveness Analysis Concerning the Surveillance of Hepatocellular Carcinoma with Contrast Enhanced Ultrasonography

Ultrasound in Medicine & Biology ◽

10.1016/j.ultrasmedbio.2009.06.713 ◽

2009 ◽

Vol 35 (8) ◽

pp. S189-S190

Author(s):

Hironori Tanaka ◽

Hiroko Iijima ◽

Shuhei Nisiguchi

Keyword(s):

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Contrast Enhanced ◽

Contrast Enhanced Ultrasonography

Download Full-text